Volume | 25 |
|
|||||
News | - |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
NKGen Biotech Inc | NKGNW | NASDAQ | Equity Warrant |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.11 | 0.11 | 0.11 | 0.1188 |
Trades | Shares Traded | Average Volume |
---|---|---|
2 | 25 | - |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
09:01:47 | 25 | 0.11 | USD |
NKGen Biotech Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
27.8M | 21.89M | - | 0 | -82.95M | -3.79 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
News NKGen Biotech
Date | Time | Source | Heading |
---|---|---|---|
5/20/2024 | 15:55 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
5/17/2024 | 16:01 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
5/13/2024 | 15:54 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities.. |
5/13/2024 | 07:05 | Edgar (US Regulatory) | Form 8-K - Current report |
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
NKGNW Historical
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing our proprietary SNK (super-activated) platform. Spearheading our industry disrupting technology are our Senior Leadership, Senior Advisors and Management Team. Together they bring a wealth of knowledge and expertise in neurodegeneration and immune-oncology and are passionate and excited about the work we are doing to strengthen the immune system. |